Granulomatous hepatitis caused by B.C.G. injection during immunotherapy of a malignant melanoma.
The authors report a case of granulomatous hepatitis after treatment by B.C.G. in a patient with malignant melanoma. The patient was treated for one year by an association of chemotherapy and lyophilized B.C.G. (Pasteur Institute). Aside from the rarity of the localization the importance of this observation resides in the discovery of B.C.G. after auramine staining in the liver suggesting that the hepatic lesions were linked to the in situ presence of mycobacteria.
D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006505:Hepatitis / Q000209:etiology* / Q000382:microbiology / Q000473:pathology; D006801:Humans; D008545:Melanoma / Q000150:complications / Q000628:therapy*; D008875:Middle Aged; D009163:Mycobacterium bovis / Q000302:isolation & purification; D009362:Neoplasm Metastasis; D013274:Stomach Neoplasms / Q000628:therapy*
D001500:BCG Vaccine